Total Payments
$474,204
2024 Payments
$182,692
Companies
25
Transactions
500
Medicare Patients
3,108
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$318,646 (67.2%)
Consulting$79,542 (16.8%)
Travel$57,797 (12.2%)
Food & Beverage$11,084 (2.3%)
Research$6,954 (1.5%)
Education$179.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $289,606 | 79 | 61.1% |
| Consulting Fee | $79,542 | 28 | 16.8% |
| Travel and Lodging | $57,797 | 191 | 12.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $29,040 | 5 | 6.1% |
| Food and Beverage | $11,084 | 189 | 2.3% |
| Unspecified | $6,954 | 6 | 1.5% |
| Education | $179.94 | 2 | 0.0% |
Payments by Type
General
$467,249
494 transactions
Research
$6,954
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $220,946 | 198 | $0 (2024) |
| Exelixis Inc. | $84,962 | 115 | $0 (2024) |
| Incyte Corporation | $55,633 | 61 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $41,806 | 35 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $16,339 | 10 | $0 (2024) |
| Eisai Inc. | $11,437 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,989 | 9 | $0 (2024) |
| Celgene Corporation | $7,196 | 3 | $0 (2019) |
| Ipsen Biopharmaceuticals, Inc | $4,400 | 1 | $0 (2019) |
| Genentech USA, Inc. | $4,080 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182,692 | 201 | AstraZeneca Pharmaceuticals LP ($58,486) |
| 2023 | $184,514 | 176 | AstraZeneca Pharmaceuticals LP ($126,279) |
| 2022 | $58,554 | 64 | AstraZeneca Pharmaceuticals LP ($36,182) |
| 2021 | $11,295 | 7 | Incyte Corporation ($6,582) |
| 2020 | $6,895 | 7 | F. Hoffmann-La Roche AG ($2,624) |
| 2019 | $17,522 | 21 | Exelixis Inc. ($5,573) |
| 2018 | $12,573 | 22 | Celgene Corporation ($6,310) |
| 2017 | $158.85 | 2 | Genentech, Inc. ($94.68) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $63.51 | General |
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $40.28 | General |
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $37.82 | General |
| 12/15/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $99.77 | General |
| 12/15/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $96.57 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $11,505.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Travel and Lodging | In-kind items and services | $46.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Travel and Lodging | In-kind items and services | $35.88 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $33.37 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Travel and Lodging | In-kind items and services | $29.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/25/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,975.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $696.96 | General |
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $288.91 | General |
| 11/20/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $146.55 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $76.72 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 11/12/2024 | Incyte Corporation | PEMAZYRE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/10/2024 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | In-kind items and services | $248.57 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-115-ST-001 - Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered oral | Celgene Corporation | $3,444 | 1 |
| AN OPEN-LABEL, MULTICENTER PHASE Ib STUDY OF THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH BEVACIZUMAB ANDOR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS | F. Hoffmann-La Roche AG | $2,624 | 4 |
| Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered orally to subjects w/ advanced solid tumors & hematologic (CC-115-ST-001) | Celgene Corporation | $886.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 115 | 192 | $45,736 | $19,392 |
| 2022 | 10 | 241 | 3,183 | $414,311 | $113,533 |
| 2021 | 35 | 1,238 | 21,182 | $1.5M | $463,437 |
| 2020 | 42 | 1,514 | 31,834 | $1.8M | $616,084 |
Total Patients
3,108
Total Services
56,391
Medicare Billing
$1.2M
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 50 | $11,900 | $5,621 | 47.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 45 | $10,710 | $4,479 | 41.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $9,308 | $3,285 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 39 | $6,162 | $2,916 | 47.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $4,654 | $1,708 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 19 | $3,002 | $1,384 | 46.1% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 11 | 2,400 | $321,352 | $91,938 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 70 | $19,904 | $6,782 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $18,900 | $5,608 | 29.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 43 | 45 | $32,085 | $4,768 | 14.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 21 | $7,701 | $2,805 | 36.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 12 | 12 | $4,056 | $658.03 | 16.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 23 | 39 | $5,148 | $509.03 | 9.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 11 | 17 | $3,196 | $420.76 | 13.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 16 | 288 | $837.50 | $27.58 | 3.3% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2022 | 23 | 256 | $1,132 | $17.28 | 1.5% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 34 | 8,004 | $1.1M | $304,896 | 28.1% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 15 | 17 | $140,678 | $38,462 | 27.3% |
| J9041 | Injection, bortezomib (velcade), 0.1 mg | Office | 2021 | 18 | 938 | $131,025 | $33,044 | 25.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 172 | 194 | $35,292 | $22,773 | 64.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 120 | $16,747 | $12,239 | 73.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 50 | 50 | $10,928 | $8,874 | 81.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 12 | 56 | $20,139 | $8,338 | 41.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 49 | $12,777 | $7,016 | 54.9% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 60 | 80 | $6,777 | $4,606 | 68.0% |
About Amit Mahipal
Amit Mahipal is a Hematology & Oncology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1417148180.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amit Mahipal has received a total of $474,204 in payments from pharmaceutical and medical device companies, with $182,692 received in 2024. These payments were reported across 500 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($289,606).
As a Medicare-enrolled provider, Mahipal has provided services to 3,108 Medicare beneficiaries, totaling 56,391 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Rochester, MN
- Active Since 08/07/2007
- Last Updated 08/18/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417148180
Products in Payments
- IMFINZI (Biological) $198,665
- CABOMETYX (Drug) $54,353
- PEMAZYRE (Drug) $41,017
- LYTGOBI (Drug) $26,699
- LONSURF (Drug) $12,115
- ZIIHERA (Drug) $11,822
- Lenvima (Drug) $11,437
- Cabometyx (Drug) $9,850
- ONIVYDE (Drug) $4,400
- CC-115 (Drug) $4,330
- TRUSELTIQ (Drug) $3,243
- CC-223 (Drug) $2,866
- Tecentriq (Biological) $2,783
- TEVIMBRA (Drug) $2,250
- TECENTRIQ (Biological) $1,809
- Vyloy (Drug) $1,401
- KEYTRUDA (Biological) $594.10
- Avastin (Biological) $311.45
- LYNPARZA (Drug) $254.68
- Stivarga (Drug) $135.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028
Dr. Alok Khorana, M.d, M.D
Hematology & Oncology — Payments: $205,803
Hematology & Oncology $205,803